FDA delays Lymphoseek decision

FDA extended the PDUFA date by three months for an NDA from Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB) for Lymphoseek tilmanocept for use in intraoperative lymphatic mapping. The new date is Sept. ...